Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Zhou, Zhiyong ^a   Wagar, Nick ^a   DeVos, Joshua R ^a   Rottinghaus, Erin ^a   Diallo, Karidia ^a   Nguyen, Duc B ^b   Bassey, Orji ^c   Ugbena, Richard ^c   Wadonda Kabondo, Nellie ^d   McConnell, Michelle S ^a,e   Zulu, Isaac ^f   Chilima, Benson ^d   Nkengasong, John ^a   Yang, Chunfu ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CDC GAP   (Nigeria)

^d MINISTRY OF HEALTH   (Malawi)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

^f Global AIDS Program CDC Zambia   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; AMINO ACID; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ACCURACY; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD EXAMINATION; CONTROLLED STUDY; COST CONTROL; DRIED BLOOD SPOT; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; MALAWI; MOLECULAR PHYLOGENY; NIGERIA; NUCLEOTIDE SEQUENCE; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; STRUCTURAL GENE; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; BIOASSAY; BLOOD; CLASSIFICATION; COST; DEVELOPING COUNTRY; DRIED BLOOD SPOT TESTING; ECONOMICS; GENETICS; GENOTYPING TECHNIQUE; HEALTH CARE PLANNING; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MOLECULAR GENETICS; MUTATION; REPRODUCIBILITY; SEQUENCE HOMOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACIDS; BASE SEQUENCE; BIOLOGICAL ASSAY; COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; DRIED BLOOD SPOT TESTING; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HEALTH RESOURCES; HIV INFECTIONS; HIV-1; HUMANS; INDICATORS AND REAGENTS; MOLECULAR SEQUENCE DATA; MUTATION; POPULATION SURVEILLANCE; REPRODUCIBILITY OF RESULTS; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 81755176137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028184     Document Type: Article

References (52)

1. Geretti AM, (2007) Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 20: 22-32.
2. Bennett DE, (2006) The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis 19: 607-614.
3. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, et al. (2008) World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 13 (Suppl 2): 49-57.
4. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D, (2008) World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 13 (Suppl 2): 15-23.
5. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2008) World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. PLoS One 13 (Suppl 2): e4724.
6. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, et al. (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med 16: 266-285.
7. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, et al. (2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368: 505-510.
8. Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, et al. (2004) Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 35: 126-130.
9. Jagodzinski LL, Cooley JD, Weber M, Michael NL, (2003) Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol 41: 998-1003.
10. Saravanan S, Vidya M, Balakrishnan P, Kumarasamy N, Solomon SS, et al. (2009) Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods 159: 211-216.
11. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, et al. (1999) Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 37: 2291-2296.
12. Aghokeng AF, Mpoudi-Ngole E, Chia JE, Edoul EM, Delaporte E, et al. (2011) High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity. J Clin Microbiol 49: 1635-1641.
13. Beddows S, Galpin S, Kazmi SH, Ashraf A, Johargy A, et al. (2003) Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol 70: 337-342.
14. Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, et al. (2001) Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J Acquir Immune Defic Syndr 28: 254-258.
15. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF, (2008) The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 13 (Suppl 2): 1-13.
16. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A,et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 163: 505-508.
17. Eshleman SH, Hackett J Jr, Swanson P, Cunningham SP, Drews B, et al. (2004) Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol 42: 2711-2717.
18. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, et al. (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288: 181-188.
19. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, et al. (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37: 113-128.
20. Buckton AJ, (2008) New methods for the surveillance of HIV drug resistance in the resource poor world. Curr Opin Infect Dis 21: 653-658.
21. WHO, (2010) WHO/HIVResNet HIV Drug Resistance Laboratory Strategy. http://www.who.int/hiv/pub/drugresistance/hiv_reslab_strategy.pdf. Accessed 2010 Sep 3.
22. Yang C, McNulty A, Diallo K, Zhang J, Titanji B, et al. (2010) Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol 48: 3158-3164.
23. WHO, (2010) WHO Manual for HIV drug resiatance testing using dried blood spot specimens. http://www.who.int/hiv/topics/drugresistance/dbs_protocol.pdf. Accessed 2010, Sep 3.
24. McConnell M, Jariyasethpong T, Chantharojwong N, Utenpitak C, Zhou Z, et al. (2010) Low level HIV-1 viremia in Thai women 24 weeks after treatment initiation with NNRTI-based ART was not associated with prior single-dose Nevirapine exposure or viral resistance mutations. 17th Conference on Retroviruses and Opportunistic Infections Poster Abstracts #502, page 243, Sanfrancisco, CA, USA.
25. Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, et al. (2010) Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med 7: e1000233.
26. Harrigan PR, Dong W, Wynhoven B, Mo T, Hall T, et al. (2002) Performance of ReCall basecalling software for high-throughput HIV drug resistance basecalling using "in-house" methods. The XIV international AIDS Conference, Barcelona, Spain, July 7-12, Abstract #TuPeB4598.
27. Tamura K DJ, Neil M, Kumar S, (2007) MEGA4: Molecular evolutionary genetics analysis software version 4.0. Mol Biol Evol 24: 1596-1599.
28. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
29. Hall TA, (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
30. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800.
31. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
32. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 199: 693-701.
33. McNulty A, Jennings C, Bennett D, Fitzgibbon J, Bremer JW, et al. (2007) Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 45: 517-521.
34. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG, (2010) Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev 12: 195-208.
35. Garrido C, Zahonero N, Fernandes D, Serrano D, Silva AR, et al. (2008) Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 61: 694-698.
36. Garcia-Lerma JG, McNulty A, Jennings C, Huang D, Heneine W, et al. (2009) Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. J Antimicrob Chemother 64: 33-36.
37. Goodenow M, Huet T, Saurin W, Kwok S, Sninsky J, et al. (1989) HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr 2: 344-352.
38. Hearps AC, Ryan CE, Morris LM, Plate MM, Greengrass V, et al. (2010) Stability of dried blood spots for HIV-1 drug resistance analysis. Curr HIV Res 8: 134-140.
39. Kijak GH, Simon V, Balfe P, Vanderhoeven J, Pampuro SE, et al. (2002) Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol 76: 7000-7009.
40. Lira R, Valdez-Salazar H, Vazquez-Rosales G, Rojas-Montes O, Ruiz-Tachiquin M, et al. (2010) Genotypic testing for HIV-1 drug resistance using dried blood samples. Arch Virol 155: 1117-1125.
41. Parkin NT, Fitzgibbon J, Bremer J, Bertagnolio S, (2009) HIV drug resistance genotyping external quality assurance (EQA) for laboratories in the World Health Organization (WHO) ResNet during 2007-2009. Antivir Ther 14 (suppl 1): A162.
42. Galli RA, Sattha B, Wynhoven B, O'Shaughnessy MV, Harrigan PR, (2003) Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance. J Clin Microbiol 41: 2900-2907.
43. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, et al. (2001) High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol 39: 1522-1529.
44. Chen JH, Wong KH, Chan K, Lam HY, Lee SS, et al. (2007) Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J Clin Virol 39: 125-131.
45. Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, et al. (2005) Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J Clin Microbiol 43: 813-817.
46. Eshleman SH, Jones D, Flys T, Petrauskene O, Jackson JB, (2003) Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq HIV-1 Genotyping System. Biotechniques 35: 614-618, 620, 622.
47. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, et al. (2001) Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). Aids 15: 1951-1957.
48. Mracna M, Becker-Pergola G, Dileanis J, Guay LA, Cunningham S, et al. (2001) Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J Clin Microbiol 39: 4323-4327.
49. Abegaz WE, Grossman Z, Wolday D, Ram D, Kaplan J, et al. (2008) Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 13 (Suppl 2): 89-94.
50. Hallack R, Doherty LE, Wethers JA, Parker MM, (2008) Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol 41: 283-287.
51. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, et al. (2008) HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother 61: 1217-1220.
52. Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, et al. (2007) High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 21: 2503-2511.